Feature|Articles|May 13, 2026

AUA 2026 preview: Practice-changing trials in benign urology

Fact checked by: Benjamin P. Saylor, Strategic Content Lead

A comprehensive guide to the practice-changing, paradigm-shifting studies across benign urologic conditions.

At the 2026 Annual Meeting of the American Urological Association in Washington, DC, the P2 plenary abstracts in benign urology are set to spotlight emerging technologies and late-breaking clinical data across stone disease, benign prostatic hyperplasia (BPH), and overactive bladder care. Presentations will feature pivotal trial updates tied to several recently cleared or approved devices, including the FDA-cleared Break Wave lithotripsy system for anesthesia-free stone treatment and the Urocross Expander System for lower urinary tract symptoms (LUTS) secondary to BPH.

Related to this article

September 21st, 2026

FDA grants breakthrough device designation to urine ID/AST panel

The assay is designed to enable faster pathogen identification and susceptibility testing to guide UTI management.

September 16th, 2026

Patient unawareness rivals diagnostic gaps as a barrier in functional urology

Early neurophysiology and pressure-flow research directly underpin modern urodynamics, whereas Turner-Warwick's restorative philosophy, according to Sasha Vereecken, BScN, RN.

October 5th, 2026

2026 AUA/SUO NMIBC guideline: Key updates for clinical practice

This FAQ outlines key recommendations and practical takeaways from the AUA/SUO guideline amendment on the diagnosis and treatment of NMIBC.

October 2nd, 2026

The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD

Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.